DOI QR코드

DOI QR Code

The Prostaglandin Synthase 2/cyclooxygenase 2 (PTGS2/COX2) rs5277 Polymorphism Does not Influence Risk of Colorectal Cancer in an Iranian Population

  • Khorshidi, Fatemeh ;
  • Haghighi, Mahdi Montazer ;
  • Mojarad, Ehsan Nazemalhosseini ;
  • Azimzadeh, Pedram ;
  • Damavand, Behzad ;
  • Vahedi, Mohsen ;
  • Almasi, Shohreh ;
  • Aghdaei, Hamid Asadzadeh ;
  • Zali, Mohammad Reza
  • Published : 2014.04.30

Abstract

Background: The prostaglandin-endoperoxide synthase 2 [PTGS2, commonly known as cyclooxygenase-2 (COX-2)] is an enzyme induced by proinflammatory stimuli that is often overexpressed in malignant tissue and involved in the synthesis of prostaglandins and thromboxanes, regulators of processes such as inflammation, cell proliferation, and angiogenesis, all relevant for cancer development. We investigated whether a functional genetic polymorphism, rs5277, in COX-2 may have a risk-modifying effect on sporadic colorectal cancer in an Iranian population. Materials and Methods: We conducted a case-control study on 167 patients with colorectal cancer and 197 cancer-free controls in Taleghani Hospital in Tehran, Iran, between 2007 and 2011. Peripheral blood samples of both groups were processed for DNA extraction and genotyping of the COX-2 gene polymorphism (rs5277) using PCR-RFLP. RFLP results were confirmed by direct sequencing. Logistic regression analysis was performed to calculate the adjusted odds ratio (OR) and 95% confidence interval (95% CI). Results: There was no significant difference in the distribution of COX-2 gene rs5277 polymorphism genotype and the allelic form, among CRC patients compared with the healthy control group (p: 0.867). Conclusions: Our results suggest that rs5277 polymorphism in COX2 could not be a good prognostic indicator for patients with CRC.

Keywords

Colorectal cancer;cyclooxygenase-2;genetic polymorphism;Iran

References

  1. Yu KD, Chen AX, Yang C, et al (2010). Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res and Treatment, 122, 251-7. https://doi.org/10.1007/s10549-009-0688-3
  2. Zhang H, Sun XF (2002). Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol, 97, 1037-41. https://doi.org/10.1111/j.1572-0241.2002.05625.x
  3. Tan W, J Wu, X Zhang, et al (2007). Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis, 28, 1197-201. https://doi.org/10.1093/carcin/bgl242
  4. Siezen CLE, Tijhuis MJ, Kram NR, et al (2006). Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor [Delta]. Pharmacogenet Genomics, 16, 43. https://doi.org/10.1097/01.fpc.0000182778.03180.f3
  5. Siezen CLE, van Leeuwen AIM, Kram NR, et al (2005). Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis, 26, 449-57.
  6. Soumaoro LT, Uetake H, Higuchi T, et al (2004). Cyclooxygenase-2 expression. Clin Cancer Res, 10, 8465-71. https://doi.org/10.1158/1078-0432.CCR-04-0653
  7. Thompson CL, Plummer SJ, Merkulova A, et al (2009). No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J Gastroenterol, 15, 2240. https://doi.org/10.3748/wjg.15.2240
  8. Tomozawa S, Tsuno N, Sunami E, et al (2000). Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer, 83, 324. https://doi.org/10.1054/bjoc.2000.1270
  9. Ulrich CM, Whitton J, Yu JH, et al (2005). PTGS2 (COX-2)− 765G> C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev, 14, 616-9. https://doi.org/10.1158/1055-9965.EPI-04-0510
  10. Vane J, Bakhle Y, Botting R (1998). Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol, 38, 97-120. https://doi.org/10.1146/annurev.pharmtox.38.1.97
  11. Xaubet A, Fu W, Li M, et al (2010). A haplotype of cyclooxygenase-2 gene is associated with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis, 27, 121-30.
  12. Pereira C, Medeiros RM, Dinis-Ribeiro MJ (2009). Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: are conclusive results available? Eur J Gastroenterol Hepatol, 21, 76-91. https://doi.org/10.1097/MEG.0b013e32830ce7ba
  13. Menter DG, Schilsky RL, DuBois RN (2010). Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res, 16, 1384-90. https://doi.org/10.1158/1078-0432.CCR-09-0788
  14. Pan F, Tian J, Pan Y, Zhang Y (1941). Lack of Association of the cyclooxygenase 8473 T>C polymorphism with lung cancer: evidence from 9841 subjects. Asian Pac J Cancer Prev, 8, 1941-5.
  15. Park KS, Woo M, Nam JH, Kim JC (2006). Start codon polymorphisms in the vitamin D receptor and colorectal cancer risk. Cancer Lett, 237, 199-206. https://doi.org/10.1016/j.canlet.2005.05.048
  16. Pereira C, Medeiros RM, Dinis-Ribeiro MJ (2009). Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: are conclusive results available? Eur J Gastroenterol Hepatol, 21, 76. https://doi.org/10.1097/MEG.0b013e32830ce7ba
  17. Poole EM, Bigler J, Whitton J, et al (2007). Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps. Carcinogenesis, 28, 1259-63. https://doi.org/10.1093/carcin/bgm026
  18. Rhodes JM,BJ Campbell (2002). Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med, 8, 10-6. https://doi.org/10.1016/S1471-4914(01)02194-3
  19. Sheehan KM, Sheahan K, O’Donoghue DP, et al (1999). The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA-J Am Med Assoc, 282, 1254-7. https://doi.org/10.1001/jama.282.13.1254
  20. Siezen CLE, Bueno-de-Mesquita HB, Peeters PHM, et al (2006). Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. Int J Cancer, 119, 297-303. https://doi.org/10.1002/ijc.21858
  21. Lashner BA, Silverstein MD, Hanauer SB (1989). Hazard rates for dysplasia and cancer in ulcerative colitis. Digest Dis Sci, 34, 1536-41. https://doi.org/10.1007/BF01537106
  22. Kanaoka S, Takai T, Yoshida K (2007). Cyclooxygenase-2 and tumor biology. Adv Clin Chem, 43, 59-78. https://doi.org/10.1016/S0065-2423(06)43002-X
  23. Khorshidi F, Mohebbi SR, Haghighi MM, et al (2013). Polymorphism− 765G> C in cyclooxygenase-2 and risk of colorectal cancer. Lab Med, 44, 14-8. https://doi.org/10.1309/LMVAX2QHHIBWY1H7
  24. Koh W, Yuan J, Van Den Berg D, Lee H, Yu M (2004). Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Bri J Cancer, 90, 1760-4.
  25. Lee TS, Jeon YT, Kim JW, et al (2007). Lack of association of the cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphism with risk of cervical cancer in korean population. Ann NY Acad Sci, 1095, 134-42. https://doi.org/10.1196/annals.1397.017
  26. Lennard-Jones J, Morson B, Ritchie J, et al (1977). Cancer in colitis: assessment of the individual risk by clinical and histological criteria. Gastroenterology, 73, 1280.
  27. Lin HJ, Lakkides KM, Keku TO, et al (2002). Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev, 11, 1305-15.
  28. Loktionov A (2004). Common gene polymorphisms, cancer progression and prognosis. Cancer Lett, 208, 1-33. https://doi.org/10.1016/j.canlet.2004.02.009
  29. Lubbe SJ, Pittman AM, Matijssen C, et al (2011). Evaluation of germline BMP4 mutation as a cause of colorectal cancer. Hum Mutat, 32, 1928-38. https://doi.org/10.1002/humu.21376
  30. Mahmoudi T, Mohebbi SR, Pourhoseingholi MA, et al (2010). Vitamin D receptor gene ApaI polymorphism is associated with susceptibility to colorectal cancer. Digest Dis Sci, 55, 2008-13. https://doi.org/10.1007/s10620-009-0989-8
  31. Danforth KN, Hayes RB, Rodriguez C, et al (2008). Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case–control studies. Carcinogenesis, 29, 568-72.
  32. Cheng I, Liu X, Plummer S, et al (2007). COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer, 97, 557-61. https://doi.org/10.1038/sj.bjc.6603874
  33. Cox D, Pontes C, Guino E, et al (2004). Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer, 91, 339-43.
  34. Cox DG, Buring J, Hankinson SE, Hunter DJ (2007). A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Res, 9, 3.
  35. Dubois RN, Abramson SB, Crofford L, et al (1998). Cyclooxygenase in biology and disease. FASEB J, 12, 1063-73.
  36. Eisinger AL, Prescott SM, Jones DA, Stafforini DM (2007). The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostaglandins & Other Lipid Mediators, 82, 147-54. https://doi.org/10.1016/j.prostaglandins.2006.05.026
  37. Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC (2004). Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis, 25, 2467-72. https://doi.org/10.1093/carcin/bgh260
  38. Gunter MJ, Canzian F, Landi S, et al (2006). Inflammationrelated gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev, 15, 1126-31. https://doi.org/10.1158/1055-9965.EPI-06-0042
  39. Hamajima N, Takezaki T, Matsuo K, et al (2001). Genotype frequencies of cyclooxygenease 2 (COX2) rare polymorphisms for Japanese with and without colorectal cancer. Asian Pac J Cancer Prev, 2, 57-62.
  40. Hou L, Grillo P, Zhu ZZ, et al (2007). COX1 and COX2 polymorphisms and gastric cancer risk in a polish population. Anticancer Res, 27, 4243-7.
  41. Bakhle Y (2001). COX-2 and cancer: a new approach to an old problem. Br J Pharmacol, 134, 1137-50. https://doi.org/10.1038/sj.bjp.0704365
  42. Barry EL, Sansbury LB, Grau MV, et al (2009). Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence—data from a randomized clinical trial. Cancer Epidemiol Biomarkers and Prev, 18, 2726-33. https://doi.org/10.1158/1055-9965.EPI-09-0363
  43. Brown JR, DuBois RN (2005). COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol, 23, 2840-55.
  44. Campa D, Zienolddiny S, Maggini V, et al (2004). Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis, 25, 229-35.
  45. Cao Y, Prescott SM (2002). Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cellular Physiol, 190, 279-86. https://doi.org/10.1002/jcp.10068

Cited by

  1. Intronic Polymorphisms of the SMAD7 Gene in Association with Colorectal Cancer vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.41